DecisionRx Announces $100 Million Credit Facility with Carlyle

Funds to Support Delivery of DecisionRx’s Comprehensive Medication Therapy Optimization Program DecisionRx, Inc., a value-based healthcare company reducing the cost of care by helping physicians eliminate medication failure, today announced that it has entered into a $100 million credit facility with global investment firm Carlyle. The financing will support the cost-bearing that is key to DecisionRx’s unique business model:  DecisionRx can assume the full cost of delivering Medication Therapy Optimization to patients of Accountable Care Organizations, Medicare Advantage Plans, and self-insured employers. The facility is expected to fund lab testing and comprehensive medication reviews by DecisionRx pharmacists for over 100,000 patients. Medication Therapy Optimization has been shown to reduce the total cost of care per Medicare patient by over $3,600 per year. “This transaction strongly validates investors’ belief in our innovative approach to improving patient outcomes by helping providers avoid medication failure at scale. Much attention is given to buying prescription medications at the right price, but our focus is on selecting the right medications in the first place,” said DecisionRx CEO, James Wallace. “Our proprietary platform disrupts the one-size-fits-all prescribing paradigm. We’ve eliminated the barriers that prevent physicians from delivering the highest standard of personalized medication therapy supported by clinical science—in partnership wi...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: Health IT Company Healthcare IT Akhil Bansal Aon Aon Securities Carlyle DecisionRx Health IT Funding Health IT Fundings Health IT Investment James Wallace Sourna Daneshvar Source Type: blogs